二肽基肽酶4及其生理底物在心肌缺血再灌注损伤中的作用

心肌缺血再灌注损伤(MIRI)发生在体外循环心内直视手术、心血管介入和溶栓等治疗后,是导致治疗后患者心功能不全、心力衰竭甚至死亡的最主要原因。近年来研究发现,内源性活性肽的释放可以缓解MIRI的产生,通过调节内源性肽的功能和作用可能是治疗MIRI最有效的途径之一。二肽基肽酶4(DPP4)是哺乳动物体内重要的丝氨酸蛋白酶,具有水解内源性肽的酶活性,其在体内的功能作用主要是代谢体内的短肽,包括生长因子、激素等。该综述通过阐述DPP4对内源性肽的水解作用在MIRI中的影响,旨在更好地认识并寻找有效的治疗靶点,最终为MIRI的治疗作用提供新的思路。

The role of dipeptidyl peptidase 4 and its physiological substrate in myocardial ischemia/reperfusion injury

Myocardial ischemia/reperfusion injury (MIRI) occurs after cardiopulmonary bypass open heart surgery, cardiovascular intervention and thrombolytic therapy, which is the most important cause of cardiac insufficiency, heart failure, and even death in patients after treatment. In recent years, studies have found that the release of endogenous active peptides can alleviate the production of MIRI, and regulating the function and action of endogenous peptides may be one of the most effective ways to treat MIRI. Dipeptidyl peptidase 4 (DPP4) is an important serine protease in mammals, with enzymatic activity to hydrolyze endogenous peptides. Its primary physiological function is to metabolize short peptides, including growth factors, hormones, etc. This review aims to better understand and search for effective therapeutic targets by elucidating the impact of DPP4 on the hydrolysis of endogenous peptides in MIRI, and ultimately provide new ideas for the therapeutic effects of MIRI.